Trial Profile
A Phase I Open Label Non-comparative Study Evaluating the Safety of a Single, Unilateral, Subretinal Administration of CNTO 2476 in Advanced Retinitis Pigmentosa
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 13 May 2014
Price :
$35
*
At a glance
- Drugs Palucorcel (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Centocor
- 13 May 2014 New trial record